Back to news

Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

Globe Newswire•16/11/2026•07:30 ET
1

Key Highlights

  • ➤33% (8 of 24) evaluable patients improved FVC at Week 12 in blinded pooled data
  • ➤Blinded pooled observations do not establish treatment effect or permit placebo comparisons
  • ➤90 patients randomized, reaching 75% of planned enrollment; topline data expected in 2027
  • ➤92% of participants remained on or completed the study; no treatment-related serious adverse events
  • ➤$36.5 million cash, equivalents and marketable securities expected to fund operations into Q1 2028

Expert Statements

Brian Windsor, President and Chief Executive Officer of Rein Therapeutics

“During the third quarter, we continued to make rapid progress in our Phase 2 RENEW trial for LTI-03 supported by strong enrollment and investigator enthusiasm. As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need. We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027.”

Cory Hogaboam, Chief Scientific Officer of Rein Therapeutics

“Blinded interim data from our ongoing Phase 2 RENEW trial provides an early look at the safety, tolerability and lung function trends we are observing across the study population. The improvements in FVC from baseline observed in 33% of evaluable patients is particularly encouraging, as improvements in lung function are not expected in this patient population. In addition to the lung function improvements we are seeing in the study, adverse events across all patients have been mild to moderate, with no serious adverse events attributable to the drug and low discontinuation rates, with 92% of participants remaining on or completing the study. While the study remains blinded, these observations collectively strengthen our belief that LTI-03 has the potential to transform the treatment landscape for IPF.”

* 33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12 * From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12 * Low discontinuation rates, and favorable safety and tolerability observed across placebo and treatment groups, with no serious adverse events assessed as related to study treatment * Study has achieved 75% enrollment, with 90 patients randomized to date; on track to report topline data in 2027 AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF). The Company also reported financial results for the third quarter ended September 30, 2026.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in